Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures

Reuters04-09 19:45

Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures

Jazz Pharmaceuticals flagged new clinical findings for Epidiolex, with results set for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.
An intermediate analysis from ongoing EpiCom Phase 3b/4 study showed Epidiolex use in tuberous sclerosis complex patients was linked to improved caregiver- and clinician-reported behavioral outcomes.
Claims-based analysis in more than 7,800 patients identified factors tied to staying on Epidiolex across Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies.
Separate DUET open-label study analysis in adults with narcolepsy indicated higher-than-recommended Xywav dosing was associated with improved patient-reported cognition, functioning, work productivity, and overall disease burden versus standard dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604090745PR_NEWS_USPR_____SF29267) on April 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626181676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626181676","market":"us","top_or_hot":-1,"title":"Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Jazz Pharmaceuticals flagged new clinical findings for Epidiolex, with results set for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.\n        </li>\n<li>\n          An intermediate analysis from ongoing EpiCom Phase 3b/4 study showed Epidiolex use in tuberous sclerosis complex patients was linked to improved caregiver- and clinician-reported behavioral outcomes.\n        </li>\n<li>\n          Claims-based analysis in more than 7,800 patients identified factors tied to staying on Epidiolex across Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies.\n        </li>\n<li>\n          Separate DUET open-label study analysis in adults with narcolepsy indicated higher-than-recommended Xywav dosing was associated with improved patient-reported cognition, functioning, work productivity, and overall disease burden versus standard dosing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604090745PR_NEWS_USPR_____SF29267) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-09 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Jazz Pharmaceuticals flagged new clinical findings for Epidiolex, with results set for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.\n        </li>\n<li>\n          An intermediate analysis from ongoing EpiCom Phase 3b/4 study showed Epidiolex use in tuberous sclerosis complex patients was linked to improved caregiver- and clinician-reported behavioral outcomes.\n        </li>\n<li>\n          Claims-based analysis in more than 7,800 patients identified factors tied to staying on Epidiolex across Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies.\n        </li>\n<li>\n          Separate DUET open-label study analysis in adults with narcolepsy indicated higher-than-recommended Xywav dosing was associated with improved patient-reported cognition, functioning, work productivity, and overall disease burden versus standard dosing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604090745PR_NEWS_USPR_____SF29267) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2V16.EUR","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2n29hw:1","article_id":"2626181676","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626181676","pubTimestamp":1775735143,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jazz Pharmaceuticals flagged new clinical findings for Epidiolex, with results set for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.An intermediate analysis from ongoing EpiCom Phase 3b/4 study showed Epidiolex use in tuberous sclerosis complex patients was linked to improved caregiver- and clinician-reported behavioral outcomes.Claims-based analysis in more than 7,800 patients identified factors tied to staying on Epidiolex across Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies.Separate DUET open-label study analysis in adults with narcolepsy indicated higher-than-recommended Xywav dosing was associated with improved patient-reported cognition, functioning, work productivity, and overall disease burden versus standard dosing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","JAZZ":"爵士制药","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4007":"制药"},"translate_title":"Jazz报告EpiCom分析显示Epidiolex可减少TSC癫痫发作中的行为问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures\n    \n\n\n          Jazz Pharmaceuticals flagged new clinical findings for Epidiolex, with results set for presentation at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.\n        \n\n          An intermediate analysis from ongoing EpiCom Phase 3b/4 study showed Epidiolex use in tuberous sclerosis complex patients was linked to improved caregiver- and clinician-reported behavioral outcomes.\n        \n\n          Claims-based analysis in more than 7,800 patients identified factors tied to staying on Epidiolex across Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies.\n        \n\n          Separate DUET open-label study analysis in adults with narcolepsy indicated higher-than-recommended Xywav dosing was associated with improved patient-reported cognition, functioning, work productivity, and overall disease burden versus standard dosing.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604090745PR_NEWS_USPR_____SF29267) on April 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626181676","isCrawlerRequest":true}